HIV: the benefits of prophylaxis of tuberculosis are confirmed by the ANRS TEMPRANO trial
RetourANRS TEMPRANO was coordinated by Dr Xavier Anglaret, research supervisor and IDLIC team leader at the Bordeaux population health research center (U1219, University of Bordeaux), and Professor Serge Eholie from the Infectious and Tropical Diseases Department of the Treichville University Hospital, and conducted by researchers from the Ivory Coast ANRS site, which comprises 8 other HIV care centers in Abidjan.
This long-term follow-up shows that tuberculosis chemoprophylaxis reduces not only severe morbidity, but also mortality, of HIV-infected people.
ANRS TEMPRANO has reassessed the benefits of isoniazid prophylaxis in the era of early antiretroviral treatment, and should encourage countries where the burden of tuberculosis is heavy to apply the relevant WHO recommendations.